ECRONICON OPEN ACCESS

EC PHARMACOLOGY AND TOXICOLOGY
Review Article

From Symptoms to Solutions: A Comprehensive Exploration of Verner-Morrison Syndrome and its Evolving Therapeutics

Vaishnavi Tokekar, Mihir Y Parmar*, Imtiyaz Bagban and Kautuk Shah

Department of Pharmacology, Krishna School of Pharmacy, Drs. Kiran and Pallavi Patel Global University, Krishna Edu Campus, Varnama,

***Corresponding Author:** Mihir Y Parmar, HOD and Professor, Department of Pharmacology, Krishna School of Pharmacy, Drs. Kiran and Pallavi Patel Global University, Krishna Edu Campus, Varnama, Vadodara, Gujarat, India.

Received: April 12, 2026; **Published:** May 01, 2026

Abstract

Verner-Morrison syndrome, also known as VIPoma or WDHA syndrome, is a rare endocrine disorder predominantly caused by vasoactive intestinal peptide (VIP)-secreting tumors in the pancreas. The hallmark clinical presentation includes profuse watery diarrhea, hypokalemia, and achlorhydria, significantly impacting patients' quality of life. This review summarizes the pathophysiology, clinical manifestations, diagnostic challenges, and current treatment options, including emerging pharmacological and herbal therapies. Moreover, the article discusses future directions in the management of VIPoma, emphasizing molecular insights and the potential of personalized therapies.

Keywords: *Verner-Morrison Syndrome; VIPoma; Vasoactive Intestinal Peptide (VIP); Somatostatin Analogs; Peptide Receptor Radionuclide Therapy (PRRT)*

Abbreviations

VIP: Vasoactive Intestinal Peptide; WHDA: Watery Diarrhoea, Hypokalemia, Achlorhydria; AMP: Adenosine Monophosphate; CT: Computed Tomography; MRI: Magnetic Resonance Imaging; Mtor: Mammalian Target of Rapamycin

Introduction

Verner-Morrison syndrome, which was first described by American physicians Stanley M. Verner and A. Berkeley Morrison in the year 1958, is a rare condition caused due to the VIP-secreting neuroendocrine tumors that are primarily located in the pancreas. The hypersecretion of VIP leads to the typical manifestations of watery diarrhea, hypokalemia, and achlorhydria, which are known as WDHA syndrome. Despite the low incidence of the disease, with approximately one in 10 million people diagnosed annually, its clinical management remains a challenge due to the complexity of its pathophysiology and late diagnosis [1,4]. Given the resemblance of VIPoma with other more common causes of chronic watery diarrhea, the final diagnosis is often delayed and the tumors are usually large and metastatic at the time of detection [14]. VIPomas in adults are primarily localized in the pancreas itself (>85%), however, in pediatric populations this tumor predominates in extrapancreatic locations, such as adrenal glands and sympathetic ganglia [15]. Diagnosis of the condition at an early stage and effective treatment plan formulation is vital to avoid dehydration and electrolyte imbalance that results in life-threatening situations. It should be a team effort involving clinicians, especially endocrinologists, oncologists, and gastroenterologists, for identification of the syndrome [16].

Pathophysiology

VIPomas are tumors that release excessive amounts of VIP, a peptide involved in various physiological processes such as smooth muscle relaxation, vasodilation, and the stimulation of water and electrolyte secretion in the intestines. Elevated VIP levels increase intracellular cyclic AMP (cAMP) concentrations, which causes massive fluid secretion into the intestines, leading to the hallmark watery diarrhea [2]. Furthermore, VIP also inhibits gastric acid secretion, contributing to achlorhydria, and induces hypokalemia by promoting potassium secretion in the intestines [3,5]. VIPomas are frequently malignant, and diagnosis of it is established based on elevated serum VIP levels that are typically higher than 75 pg/mL, and characteristic imaging findings. While the majority of these tumors originate in the pancreas, they can metastasize to other organs, primarily the liver and lymph nodes [6].



Figure 1: *A brief pathophysiology of occurrence of the Verner-Morrison Syndrome.*

Clinical features

The primary indications of Verner-Morrison syndrome involve severe watery diarrhea, that may exceed 3 liters per day leading to dehydration, significant reduction in weight, and imbalances in levels of electrolytes such as hypokalemia (low blood potassium levels). Achlorhydria, caused due to inhibited secretion of gastric acid, is an another salient feature of the syndrome [7]. Another manifestations like flushing and hypotension, have an probability to be observed because of the vasodilatory effects of VIP [6].

Diagnosis of VIPoma is confirmed through clinical presentation, raised serum VIP concentrations, and imaging studies that include CT scans, MRI, and somatostatin receptor scintigraphy, to locate the tumor. The diagnosis of VIPoma is often delayed as a result of the clinical symptoms being nonspecific and perhaps, due to their association with different gastrointestinal disorders [4,7].

Available treatments

- **Surgical intervention:** Surgical resection remains the most effective treatment for localized VIPomas. Distal pancreatectomy or enucleation may be performed, depending on the location of the tumor. However, due to the aggressive nature of many VIPomas,



Figure 2: *Clinical signs and symptoms observed in Verner-Morrison (WHDA) syndrome.*

surgical intervention is not always possible at the time of diagnosis [8]. Surgical resection of the tumor remains the treatment of choice in patients with pancreatic VIPoma, even in those with metastatic lesions [14]. Hepatic artery embolization is a palliative treatment in patients with unresectable hepatic metastases [16].

- **Pharmacological therapy:** Somatostatin analogs (SSAs), such as octreotide and lanreotide, are commonly used to control symptoms by inhibiting VIP secretion. These medications reduce diarrhea and improve electrolyte balance in most patients [5]. In patients who do not respond to SSAs, targeted therapies like sunitinib, a tyrosine kinase inhibitor, and everolimus, an mTOR inhibitor, have demonstrated efficacy in controlling tumor growth and alleviating symptoms [7,8]. Two molecular-targeted agents, everolimus and sunitinib malate, have been approved for the treatment of metastatic or locally advanced pNETs with promising results [14].
- **Peptide receptor radionuclide therapy (PRRT):** ^177Lu-DOTATATE, a radiolabeled somatostatin analog, targets somatostatin receptors on tumor cells, delivering targeted radiation. PRRT has shown significant promise in treating advanced, metastatic VIPomas by controlling symptoms and reducing tumor size [6].

Existing herbal treatments

While pharmacological interventions remain the primary treatment modality for VIPoma, traditional medicine, including herbal remedies, has been explored as an adjunct for managing symptoms. Various Chinese herbal formulations have been used to alleviate symptoms such as diarrhea and improve patient quality of life. The clinical evidences that support the efficacy of these treatments is still limited, and are recommended to be used cautiously along with conventional therapies [10,11].

Future approaches

The future of treatment of Verner-Morrison syndrome is centered on advancement in field of molecular biology and the identification and characterization of specific mutations in genes linked with VIPomas. Targeted therapies that are based on genetic profiling of human may aid in offering personalized treatment alternatives and enhance outcomes. Also, persisting research in immunotherapy and novel targeted agents aid in promising for more efficient and better treatment strategies. Developing another sensitive biomarkers and imaging methods may help in earlier diagnosis and thus allow for facilitating timely interventions [12,13].

Discussion

Verner-Morrison syndrome displays a complicated clinical picture as it is uncommon, rare and possesses nonspecific clinical manifestations. Early recognition is essential and significant to avoid the complications linked with electrolyte imbalances and excess dehydration. Recent management of treatment, like surgery, somatostatin analogs, targeted therapies, as well as peptide receptor radionuclide therapy, helps achieve symptom alleviation and control in tumor growth. Challenges, yet persist in treating the cases of metastatic and advanced VIPomas. Further research onto the molecular pathways and mechanisms of VIPoma and the advancement in development of tailored treatments promise and help ensure for improving and enhancing patient health outcomes [5,6].

Conclusion

Verner-Morrison syndrome is still a difficult condition to tackle due to its rare incidence and bad manifestations. Improvements in surgery, drugs, and newer therapies have enhanced management, but treating advanced cases remains problematic. Because the illness is infrequent, collective clinical experience and persistent research are extremely crucial. With ongoing advances in molecular research and new therapies, treatment can become more precise, timely, and directed toward enhancing the quality of life in patients.

Acknowledgement

I, Vaishnavi Tokekar, gratefully acknowledge the invaluable guidance and encouragement of Dr. (Prof.) Mihir Y. Parmar, whose insights and support were instrumental in the preparation of this article. Sincere thanks are also extended to colleagues for their cooperation and constructive feedback, which contributed significantly to this work. I further recognize the assistance of digital tool ChatGPT, for generating illustrative figures that enhanced the clarity of presentation. No external funding was received for this publication.

Bibliography

1. Verner JV and Morrison AB. "Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia". *American Journal of Medicine* 25.3 (1958): 374-380.
2. Bloom SR and Polak JM. "VIPoma syndrome". *Lancet* 1.8536 (1987): 14-16.
3. Lamberts SW., *et al*. "VIPoma syndrome". *American Journal of Medicine* 85.2 (1988): 203-212.
4. Modlin, I.M., *et al*. "A 5-decade analysis of 13,715 carcinoid tumors". *Cancer* 97.4 (2003): 934-959.
5. Oberg K. "The management of neuroendocrine tumors: current and future medical therapy options". *Clinical Oncology (Royal College of Radiologists (Great Britain))* 24.4 (2012): 282-293.
6. Strosberg JR., *et al*. "Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors". *New England Journal of Medicine* 376.2 (2017): 125-135.
7. Yao JC., *et al*. "Everolimus for advanced pancreatic neuroendocrine tumors". *New England Journal of Medicine* 364.6 (2011): 514-523.

8. Raymond E., *et al*. "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors". *New England Journal of Medicine* 364.6 (2011): 501-513.

9. Caplin ME., *et al*. "Lanreotide in metastatic enteropancreatic neuroendocrine tumors". *New England Journal of Medicine* 371.3 (2014): 224-233.

10. Liu X., *et al*. "The role of traditional Chinese medicine in the treatment of neuroendocrine tumors: A systematic review". *World Journal of Clinical Oncology* 8.1 (2017): 1-10.

11. Zhou Z., *et al*. "Efficacy of herbal remedies in the treatment of pancreatic neuroendocrine tumors: A review of clinical studies". *Journal of Traditional Chinese Medicine* 39.2 (2019): 191-198.

12. Rindi G., *et al*. "A common classification framework for neuroendocrine neoplasms: An international agency for research on cancer (IARC) and World Health Organization (WHO) expert consensus proposal". *Modern Pathology* 31.12 (2018): 1770-1786.

13. Zandee WT., *et al*. "Peptide receptor radionuclide therapy in patients with somatostatin receptor-positive pancreatic neuroendocrine tumors". *Journal of Clinical Oncology* 35.9 (2017): 940-948.

14. Giampatzis V., *et al*. "Pancreatic vasoactive intestinal peptide-producing tumor as a rare cause of acute diarrhea and severe hypokalemia". *Journal of Medical Cases* 14.9-10 (2023): 307-316.

15. Karele., *et al*. "All you need to know about VIPoma: Review on the latest studies". *La Presse Médicale* 53.2 (2024): 104222.

16. Helbing A., *et al*. "VIPoma". In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2026).

Volume 14 Issue 5 May 2026